Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit

Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business